The median estimated EFS for PRL3-positive patients was 3.9 months compared with 17.7 months for PRL3-negative patients based on PRL3 status at initial diagnosis, while the median estimated EFS for PRL3-positive patients was 14.6 months compared with 17.7 months for PRL3-negative patients based on PRL3 status of the most recent tumor biopsy. This evidence concerns the gene PTP4A3 and neoplasm.